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LETTER TO THE EDITOR
Potential Cost-Effectiveness
of US-Guided FNAC
in Melanoma Patients
as a Primary Procedure
and in Follow-Up
TO THE EDITORS:
We read with great interest the vivid correspondence
between the authors of recent papers in the Annals of
Surgical.1–3 The discussion focuses on a possible survival
benefit for patients treated by sentinel lymph node biopsy
(SNLB) procedure compared with observation (OBS) and
the potential cost-effectiveness of SNLB in the light of
such a supposed survival benefit, based on the third interim
results of the prospective Multicenter Selective Lymphad-
enectomy Trial-1 (MSLT-1).4
Interestingly, the discussion also focuses on the nodal
relapse rates for both arms of the MSLT-1 trail (Table 1).
Strikingly, there seems to be an increase in late relapses in
both arms, which might either be the result of selection
bias, as follow-up has not yet matured to 10 years in the
entire MSLT-1 population and thus might lead to an
overestimation of the data, or these continuous late relapses
in both arms may indicate a failure rate of completion
lymph node dissection (CLND) completeness. Interestingly
we did not see any late relapses in our submicrometastases
(\0.1 mm) patients.5–7
In light of the lack of survival benefit for the sentinel
node (SN) procedure from the point of randomization in
the MSLT-1 trial, the cost-effectiveness of the SN proce-
dure as a staging procedure is debatable. Recently a study
by Voit et al. demonstrated that presurgical ultrasound
(US)-guided fine-needle aspiration cytology (FNAC) has a
sensitivity of 65% compared with surgical SN procedure.8
Moreover, the sensitivity of US-guided FNAC increases
significantly with increasing SN tumor burden.8
Considering that only 15–30% of all stage I/II melanoma
patients are SN positive, 70– 85% are negative but still
undergo a SN procedure.4 US-guided FNAC has the poten-
tial to save 65–80% of SN-positive patients a SN staging
procedure and to save an estimated 61–92% of SN-negative
patients a surgical procedure, and the accompanying costs.
Here we would like to submit the argument for ultra-
sound-guided FNAC as a cost-effective alternative scenario
to the surgical SN procedure. For the purpose of these
calculations, based on the data by Voit et al., we considered
that 40% will undergo an US with FNAC whereas 60% will
have a benign US and will not undergo a FNAC.8 More-
over, 50% will be FNAC positive and 50% will be FNAC
negative. Finally, the negative patients will undergo routine
US follow-up (four times a year), with an average of one
FNAC.
At our centers in The Netherlands and Germany, an SN
procedure and 1 day of hospital stay would cost an average
of €1254.83. Thus, for a scenario of 100 stage I/II mela-
noma patients, the total cost would be €125,483. Moreover,
these calculations do not take into account the time spent in
the operating theatre, which could be used for other
patients, and the strain on the waiting list for operations.
For the US-guided FNAC scenario, an average ultrasound
exam would cost €58.99 (without FNAC) and a US-guided
FNAC would cost an average of €168.61 at our centers. Fig-
ure 1 shows the flowchart of US-guided-FNAC and the sum of
the costs. Total costs of US-guided FNAC as an alternative
would be €10,283.80 ? €45,831.40 = €56,115.20. This is
considerably lower than the €125,483 for 100 SN procedures,
corresponding to a cost reduction of 55%.
In reality the savings will be higher as ultrasound is
increasingly used for the follow-up of melanoma patients,
even after a negative SN or after a CLND for a positive SN. At
present, these patients undergo in an increasing number of
centers an ultrasound exam twice a year for 5–10 years. This
would lead to costs up to 2 9 5 9 100 9 €58.99 = €58,990
(without any FNAC over the entire follow-up period). Thus
the potential saving might even be much higher, approxi-
mately 70%.
Thus, US-guided FNAC emerges as an alternative and
cost-effective staging procedure compared with surgical SN,
with the potential to save up to €69,367.80 ([50%) at our
centers, plus the obvious benefits such as saving patients
unnecessary surgery, morbidity, operation theatre time, and
reducing the strain on the waiting list for operations. Therefore
there is a need to reproduce the results from the study by Voit
et al. to establish the value of US-guided FNAC.
Ann Surg Oncol (2010) 17:660–662
DOI 10.1245/s10434-009-0807-8
Alexander C. J. van Akkooi, MD1, Christiane A. Voit,
PhD2, Cornelis Verhoef, PhD1, and Alexander M. M.
Eggermont, PhD1
1Department of Surgical Oncology, Erasmus University
Medical Center—Daniel den Hoed Cancer Center, Rotter-
dam, The Netherlands;
2Department of Dermatology, Charite´, Humboldt Univer-
sity, Berlin, Germany
e-mail: a.vanakkooi@erasmusmc.nl
Published Online: 17 November 2009
 The Author(s) 2009. This article is published with open access at
Springerlink.com
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
REFERENCES
1. Morton RL, Howard K, Thompson JF. The cost-effectiveness of
sentinel node biopsy in patients with intermediate thickness
primary cutaneous melanoma. Ann Surg Oncol. 2009;16:929–40.
2. Thomas JM. Prognostic false-positivity and cost-effectiveness in
sentinel node biopsy in melanoma. Ann Surg Oncol. 2009;16(10):
2961; author reply 2962–3.
3. Thompson JF, Morton DL. In reply: cost-effectiveness of sentinel
node biopsy for melanoma. Ann Surg Oncol. 2009;16:2962–3.
4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or
nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.
5. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of
melanoma micrometastases (\0.1 mm) in sentinel nodes: are these
nodes to be considered negative? Ann Oncol. 2006;17:1578–85.
6. van Akkooi AC, Nowecki ZI, Voit C, Scha¨fer-Hesterberg G, Michej
W, de Wilt JH, et al. Sentinel node tumor burden according to the
Rotterdam criteria is the most important prognostic factor for
survival in melanoma patients: a multicenter study in 388 patients
with positive sentinel nodes. Ann Surg. 2008;248(6):949–55.
7. van Akkooi ACJ, Rutkowski P, van der Ploeg IM, et al. Long-term
follow-up of patients with minimal sentinel node tumor burden
FIG. 1 Cost-effectiveness flowchart
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TABLE 1 Nodal metastasis rate and rate of increase according to time for sentinel node (SN) and observation (OBS) arms of the Multicenter
Selective Lymphadenectomy Trial-1 (MSLT-1)
SN arm Increase OBS arm Increase Difference
0 years 15.6% 15.6% 0% 100%
3 years 18.9% (± 1.4%) 3.3% 1.1%/year 13.6% (± 1.6%) 13.6% 4.4%/year 5.3%
5 years 19.4% (± 1.4%) 0.5% 0.25%/year 16.1% (± 1.7%) 2.5% 1.25%/year 3.3%
7 years 19.6% (± 1.5%) 0.2% 0.1%/year 17.0% (± 1.7%) 0.9% 0.45%/year 2.6%
10 years 20.8% 1.2% 0.4%/year 20.5% 3.5% 1.2%/year 0.3%
From: Morton, 6th Biannual International Sentinel Node Society meeting, Sydney 2008
Increase in SN arm, years 5–10: 1.4% = 0.3%/year
Increase in OBS arm, years 5–10: 2.9% = 0.6%/year
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